Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement

Modern Pathology

Volumn 27, Issue 5, 2014, Pages 751-757

  Lee, Cheng Han ^a   Hoang, Lien N ^b   Yip, Stephen ^b   Reyes, Carolina ^c   Marino Enriquez, Adrian ^d   Eilers, Grant ^d   Tao, Derrick ^d   Chiang, Sarah ^c   Fletcher, Jonathan A ^d   Soslow, Robert A ^c   Nucci, Marisa R ^d   Oliva, Esther ^e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ANO1; endometrial stromal sarcoma; KIT; NUTM2A; NUTM2B; YWHAE

Indexed keywords

ANO 1; STEM CELL FACTOR RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG; ANO1 PROTEIN, HUMAN; CHLORIDE CHANNEL; CYCLIN D1; PROTEIN 14 3 3; TUMOR PROTEIN; YWHAE PROTEIN, HUMAN;

ARTICLE; CELL MEMBRANE; CELL SHAPE; CONTROLLED STUDY; CYTOPLASM; ENDOMETRIUM SARCOMA; EXON; FEMALE; FIBROBLAST; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; ENDOMETRIUM TUMOR; GENE REARRANGEMENT; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

14-3-3 PROTEINS; CHLORIDE CHANNELS; CYCLIN D1; ENDOMETRIAL NEOPLASMS; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; SARCOMA, ENDOMETRIAL STROMAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84899925285     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.199     Document Type: Article

References (34)

1. Lee CH, Marino-Enriquez A, Ou W, et al. Theclinicopathologic features of YWHAE-FAM22 endometrialstromal sarcomas: a histologically high-gradeand clinically aggressive tumor. Am J Surg Pathol2012;36:641-653.
2. Lee CH, Ou WB, Marino-Enriquez A, et al. 14-3-3Fusion oncogenes in high-grade endometrial stromalsarcoma. Proc Natl Acad Sci USA 2012;109:929-934.
3. Isphording A, Ali RH, Irving J, et al. YWHAE-FAM22endometrial stromal sarcoma: diagnosis by reversetranscription-polymerase chain reaction in formalinfixed,paraffin-embedded tumor. Hum Pathol 2013;44:837-843.
4. Oliva E, Young RH, Clement PB, et al. Myxoid andfibrous endometrial stromal tumors of the uterus: areport of 10 cases. Int J Gynecol Pathol 1999;18:310-319.
5. Yilmaz A, Rush DS, Soslow RA. Endometrial stromalsarcomas with unusual histologic features: a report of24 primary and metastatic tumors emphasizing fibroblasticand smooth muscle differentiation. Am J SurgPathol 2002;26:1142-1150.
6. Lee CH, Ali RH, Rouzbahman M, et al. Cyclin D1 as adiagnostic immunomarker for endometrial stromalsarcoma with YWHAE-FAM22 rearrangement. Am JSurg Pathol 2012;36:1562-1570.
7. Amant F, Tousseyn T, Coenegrachts L, et al. Case reportof a poorly differentiated uterine tumour with t(10;17)translocation and neuroectodermal phenotype. AnticancerRes 2011;31:2367-2371.
8. Lee CH, Liang CW, Espinosa I. The utility of discoveredon gastrointestinal stromal tumor 1 (DOG1) antibody insurgical pathology-the GIST of it. Adv Anat Pathol2010;17:222-232.
9. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinaseinhibitor resistance mechanisms in GIST. J Pathol2008;216:64-74.
10. Kruger S, Emig M, Lohse P, et al. The c-kit (CD117)sequence variation M541L, but not N564K, is frequentin the general population, and is not associated withCML in Caucasians. Leukemia 2006;20:354-355; discussion6-7.11.
11. Putz A, Hartmann AA, Fontes PR, et al. TP53 mutationpattern of esophageal squamous cell carcinomas in ahigh risk area (Southern Brazil): role of life stylefactors. Int J Cancer 2002;98:99-105.
12. Caudell JJ, Deavers MT, Slomovitz BM, et al. Imatinibmesylate (gleevec)-targeted kinases are expressed inuterine sarcomas. Appl Immunohistochem Mol Morphol2005;13:167-170.
13. Cossu-Rocca P, Contini M, Uras MG, et al. Tyrosinekinase receptor status in endometrial stromal sarcoma:an immunohistochemical and genetic-molecular analysis.Int J Gynecol Pathol 2012;31:570-579.
14. Geller MA, Argenta P, Bradley W, et al. Treatment andrecurrence patterns in endometrial stromal sarcomasand the relation to c-kit expression. Gynecol Oncol2004;95:632-636.
15. Hornick JL, Fletcher CD. Immunohistochemical stainingfor KIT (CD117) in soft tissue sarcomas is very limited indistribution. Am J Clin Pathol 2002;117:188-193.
16. Klein WM, Kurman RJ. Lack of expression of c-kitprotein (CD117) in mesenchymal tumors of the uterusand ovary. Int J Gynecol Pathol 2003;22:181-184.
17. Nakayama M, Mitsuhashi T, Shimizu Y, et al. Immunohistochemicalevaluation of KIT expression in sarcomasof the gynecologic region. Int J Gynecol Pathol2006;25:70-76.
18. Oliva E, Young RH, Amin MB, et al. An immunohistochemicalanalysis of endometrial stromal andsmooth muscle tumors of the uterus: a study of 54cases emphasizing the importance of using a panelbecause of overlap in immunoreactivity for individualantibodies. Am J Surg Pathol 2002;26:403-412.
19. Rushing RS, Shajahan S, Chendil D, et al. Uterinesarcomas express KIT protein but lack mutation(s) inexon 11 or 17 of c-KIT. Gynecol Oncol 2003;91:9-14.
20. Park JY, Kim KR, Nam JH. Immunohistochemicalanalysis for therapeutic targets and prognostic markersin low-grade endometrial stromal sarcoma. Int JGynecol Cancer 2013;23:81-89.
21. Liegl B, Gully C, Reich O, et al. Expression of plateletderivedgrowth factor receptor in low-grade endometrialstromal sarcomas in the absence of activatingmutations. Histopathology 2007;50:448-452.
22. Espinosa I, Lee CH, Kim MK, et al. A novel monoclonalantibody against DOG1 is a sensitive and specificmarker for gastrointestinal stromal tumors. Am J SurgPathol 2008;32:210-218.
23. Akpalo H, Lange C, Zustin J. Discovered on gastrointestinalstromal tumour 1 (DOG1): a useful immunohistochemicalmarker for diagnosing chondroblastoma.Histopathology 2012;60:1099-1106.
24. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in thedifferential diagnosis of gastrointestinal stromaltumors: a study of 1840 cases. Am J Surg Pathol2009;33:1401-1408.
25. Sah SP, McCluggage WG. DOG1 immunoreactivityin uterine leiomyosarcomas. J Clin Pathol 2013;66:40-43.
26. Goh SG, Chuah KL, Chew SH, et al. Uterine epithelioidendometrial stromal sarcoma presenting as a 'cervicalpolyp'. Ann Diagn Pathol 2005;9:101-105.
27. Butnor KJ, Burchette JL, Sporn TA, et al. The spectrumof Kit (CD117) immunoreactivity in lung and pleuraltumors: a study of 96 cases using a single-sourceantibody with a review of the literature. Arch PatholLab Med 2004;128:538-543.
28. Folpe AL, Mentzel T, Lehr HA, et al. Perivascularepithelioid cell neoplasms of soft tissue and gynecologicorigin: a clinicopathologic study of 26 cases andreview of the literature. Am J Surg Pathol 2005;29:1558-1575.
29. Makhlouf HR, Remotti HE, Ishak KG. Expression ofKIT (CD117) in angiomyolipoma. Am J Surg Pathol2002;26:493-497.
30. Rabban JT, Zaloudek CJ. A practical approach toimmunohistochemical diagnosis of ovarian germ celltumours and sex cord-stromal tumours. Histopathology2013;62:71-88.
31. Tayal S, Classen E, Bemis L, et al. C-kit expression indedifferentiated and well-differentiated liposarcomas;immunohistochemistry and genetic analysis. AnticancerRes 2005;25:2215-2220.
32. Truong LD, Shen SS. Immunohistochemical diagnosis ofrenal neoplasms. Arch Pathol Lab Med 2011;135:92-109.
33. Salvatierra A, Tarrats A, Gomez C, et al. A case of c-kitpositive high-grade stromal endometrial sarcomaresponding to imatinib mesylate. Gynecol Oncol 2006;101:545-547.
34. Edris B, Willingham SB, Weiskopf K, et al. Anti-KITmonoclonal antibody inhibits imatinib-resistant gastrointestinalstromal tumor growth. Proc Natl Acad Sci USA 2013;110:3501-3506.